The Effect of Glucagon Like Peptide (GLP)-1 in Psoriasis

The Effect of GLP-1 in Psoriasis

The objective of this study is to investigate the effect of the GLP-1 analogue Victoza® on psoriasis in a double-blinded, randomized placebo-controlled clinical trial.

Inclusion Criteria:

• Caucasians above 18 years of age
• Plaque psoriasis
• PASI score >10
• No treatment or stable treatment of psoriasis during at least 3 months before inclusion
• Steady weight through 3 months with a body mass index (BMI) above 27 kg/m2
• Normal blood pressure
• Spiral or hormonal birth control for fertile women during the entire treatment period and at least 3 days after the end of the treatment period (~5 times the plasma half-life)

Exclusion Criteria:

• Psoriasis arthritis
• Fasting plasma glucose > 7.5 mmol/L or HbA1c > 7.5%
• Type 1 diabetes
• Treatment for type 2 diabetes with GLP-1-based medicine (DDP-4-inhibitors or GLP-1-receptor-agonists)
• Heart failure, NYHA class III-IV
• Uraemia, end-stage renal disease, or any other cause of impaired renal function with s-creatinine >150 µM and/or albuminuria
• Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase (ASAT) >2 x upper normal serum levels)
• Anaemia
• Acute or chronic pancreatitis
• Struma or thyroid cancer
• Pregnancy or breast feeding
• Inability to complete the study